

Precision Medicine in NSCLC: Novel Targets for Effective Management TOOLKIT

Therapeutic Modalities for Advanced NSCLC

Resource	Web Address
Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). <i>Cancer Treat Rev.</i> 2022;106:102393.	https://www.cancertreatmentreviews.com/article/S0305-7372(22)00057-3/fulltext
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. <i>Nat Rev Clin Oncol.</i> 2021;18:327-344.	https://www.nature.com/articles/s41571-021-00470-8
Hunter FW, Barker HR, Lipert B, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. <i>Br J Cancer.</i> 2020;122:603-612.	https://www.nature.com/articles/s41416-019-0635-y
Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. <i>N Engl J Med.</i> 2022;386:241-251.	https://www.nejm.org/doi/10.1056/NEJMoa21112431

TROP2 as a Therapeutic Target in Lung Cancer

Resource	Address
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. <i>N Engl J Med.</i> 2019;380:741-751.	https://www.nejm.org/doi/10.1056/NEJMoa1814213
Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC). <i>J Clin Oncol.</i> 2022;40(16 suppl):9016.	https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9016
Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. <i>Oncotarget.</i> 2018;9:28989-29006.	https://www.oncotarget.com/article/25615/
Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. <i>J Clin Oncol.</i> 2017;35:2790-2797.	https://ascopubs.org/doi/10.1200/JCO.2016.72.1894
Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. <i>Oncotarget.</i> 2017;8:28725-28735.	https://www.oncotarget.com/article/15647/
Jänne PA, Baik C, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. <i>Cancer Discov.</i> 2022;12:74-89.	https://aacrjournals.org/cancerdiscovery/article/12/1/74/675637/Efficacy-and-Safety-of-Patritumab-Deruxtecan-HER3
Levy B, Paz-Ares L, Rixe O, et al. MA13.07 TROPION-Lung02: Initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. <i>J Thorac Oncol.</i> 2022;17(9 suppl):S91.	https://www.jto.org/article/S1556-0864(22)00493-2/fulltext

Makawita S, Meric-Bernstam F. Antibody-drug conjugates: Patient and treatment selection. <i>Am Soc Clin Oncol Educ Book</i> . 2020;40:1-10.	https://ascopubs.org/doi/10.1200/EDBK_280775
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. <i>N Engl J Med</i> . 2020;382:610-621.	https://www.nejm.org/doi/10.1056/NEJMoa1914510
Spira A, Lisberg A, Sands J, et al. OA03.03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study. <i>J Thorac Oncol</i> . 2021;16(3 suppl):S106-S107.	https://www.jto.org/article/S1556-0864(21)00322-1/fulltext
Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: Potential implications as a cancer therapeutic target. <i>J Histochem Cytochem</i> . 2011;59:701-710.	https://journals.sagepub.com/doi/10.1369/0022155411410430
Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. <i>Oncogene</i> . 2013;32:222-233.	https://www.nature.com/articles/onc201236
Trodelvy® (sacituzumab govitecan-hziy). Package insert. Gilead Sciences, Inc; 2021.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf
Zeng P, Chen MB, Zhou LN, Tang M, Liu CY, Lu PH. Impact of TROP2 expression on prognosis in solid tumors: A systematic review and meta-analysis. <i>Sci Rep</i> . 2016;6:33658.	https://www.nature.com/articles/srep33658

All URLs accessed May 11, 2023